Analysis of liver steatosis analysis and controlled attenuation parameter for grading liver steatosis in patients with chronic hepatitis B

Ren, Xinping; Xia, Shujun; Zhang, Lu; Li, Ruokun; Zhou, Wei; Ji, Ran; Zhou, Jinhua; Tian, Jingyan; Zhan, Wei

doi:10.21037/qims-19-1091

Cited by 7 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study has demonstrated that LiSA is an extremely efficient tool for assessing liver steatosis and can provide immediate results with high sensitivity; also, LiSA and CAP are highly correlated in diagnosing hepatic steatosis. 11 The cutoff value of CAP for diagnosing fatty liver (< 238dB/m, 238 ~ 258 dB/m, 259 ~ 291 dB/m, ≥ 292 dB/m) is also applicable to LiSA, because of the same detection principle and the high correlation confirmed by literature report. 12 …”

Section: Introductionmentioning

confidence: 83%

Relationship Between Thyroid Hormone and Liver Steatosis Analysis Parameter in Obese Participants: A Case-Control Study

Chen¹,

Xu³

et al. 2022

DMSO

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 83%

Relationship Between Thyroid Hormone and Liver Steatosis Analysis Parameter in Obese Participants: A Case-Control Study

Chen¹,

Xu³

et al. 2022

DMSO

View full text Add to dashboard Cite

“…Fujiwara et al ( 79 ) used the C1-6-D phased array probe to detect the LOGIQ E9 XD clear 2.0 ultrasound (GE Healthcare, USA) guided attenuation parameter (UGAP) detection and the AUROC of the UGAP-values for identifying S1, S2, and S3 of hepatic steatosis (0.900, 0.950, and 0.959) is significantly better than the AUROC of CAP values (0.829, 0.841, and 0.817), respectively. Ren et al ( 80 ) measure liver steatosis analysis (Lisa) with Hepatus, a newly developed ultrasound machine, with a 3.5-MHz phased array probe (LFP5-1U, Mindray, Re 6S, China) on 203 patients with CHB. Compared with CAP detected by FS probe, the diagnostic efficiency of Lisa for steatosis ≥ 10% was significantly better than that of CAP (AUC: 0.859 vs. 0.801, P < 0.05).…”

Section: Discussionmentioning

confidence: 99%

A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease

et al. 2022

View full text Add to dashboard Cite

Background and AimsPatients with chronic hepatitis B virus infection (CBI) with concurrent nonalcoholic fatty liver disease (NAFLD) is becoming increasingly common in clinical practice, and it is quite important to identify the etiology when hepatitis occurs. A noninvasive diagnostic model was constructed to identify patients who need antihepatitis B virus (HBV) therapies [histologic activity index (HAI) ≥ 4] in patients with CBI with concurrent NAFLD by analyzing clinical routine parameters.Approach and ResultsIn total, 303 out of 502 patients with CBI with concurrent NAFLD proven by liver biopsy from January 2017 to December 2020 in the Tianjin Second People's Hospital were enrolled and they were divided into the HBV-related inflammation (HBV-I) group (HAI ≥ 4,176 cases) and the non-HBV-I group (HAI < 4,127 cases) according to hepatic pathology. The univariate analysis and multivariate logistic regression analysis were performed on the two groups of patients, and then the HBV-I model of patients with CBI with concurrent NAFLD was constructed. The areas under receiver operating characteristic curves (AUROCs) were used to evaluate the parameters of the regression formula. Another 115 patients with CBI with concurrent NAFLD proven by liver biopsy from January 2021 to January 2022 were enrolled as the validation group. There were some statistical differences in demographic data, biochemical indicators, immune function, thyroid function, virology indicator, and blood routine indicators between the two groups (P < 0.05) and liver stiffness measurement (LSM) in the HBV-I group was significantly higher than those in the non-HBV-I group (P < 0.05). While controlled attenuation parameters (CAP) in the HBV-I group were lower than those in the non-HBV-I group (P < 0.05); (2) We developed a novel model by logistic regression analysis: HBV-I = −0.020 × CAP + 0.424 × LSM + 0.376 × lg (HBV DNA) + 0.049 × aspartate aminotransferase (AST) and the accuracy rate was 82.5%. The area under the receiver operating characteristic (AUROC) is 0.907, the cutoff value is 0.671, the sensitivity is 89.30%, the specificity is 77.80%, the positive predictive value is 90.34%, and the negative predictive value is 81.89%; (3) The AUROC of HBV-I in the validation group was 0.871 and the overall accuracy rate is 86.96%.ConclusionOur novel model HBV-I [combining CAP, LSM, lg (HBV DNA), and AST] shows promising utility for predicting HBV-I in patients with CBI with concurrent NAFLD with high sensitivity, accuracy, and repeatability, which may contribute to clinical application.

show abstract

“…According to a recent study, liver steatosis was defined with CAP ≥274 dB/m, and liver fibrosis was defined with LSM ≥8.2 kPa [ 20 ]. Although liver steatosis was more common in NAFLD, it could also occur in chronic hepatitis [ 21 , 22 ] and ALD [ 23 ]. According to published meta-analysis and prospective studies, the liver stiffness cut-off was 8.2 kPa for F ≥ 3 in CHB [ 24 ], whereas, in NAFLD, 8.2 kPa was the cut-off for F ≥ 2 [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

The association between serum albumin and depression in chronic liver disease may differ by liver histology

Cao

Qiu

et al. 2022

BMC Psychiatry

View full text Add to dashboard Cite

Background There are conflicting results regarding the association between chronic liver disease (CLD) and depression and the underlying biological mechanisms are lack of investigation. To address the impact of depression and its effects on the management of CLD, its biological marker is critical to be identified. The present study explored the association between serum albumin and depression in CLD patients and whether the association varied in different liver histological stages. Methods Based on the United States National Health and Nutrition Examination Survey 2017–2018, the data of serum albumin and depressive symptoms from 627 participants with CLD were used. Depression symptoms were assessed with the nine-item Patient Health Questionnaire (PHQ-9). We used multivariate linear regression to evaluate the association between serum albumin and PHQ-9 scores. Stratified analysis was performed according to the liver histology examined by vibration controlled transient elastography. Results Serum albumin level was inversely associated with PHQ-9 scores in the multivariate regression model after adjusting for mainly potential confounders (β = − 1.113, 95% CI: − 2.065 to − 0.162, P = 0.0221). In the subgroup analysis stratified by gender, controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), the inverse association remained significant in female (β = − 2.002, 95% CI: − 3.515 to − 0.489, P = 0.0100), patients with CAP < 274 dB/m (β = − 2.215, 95% CI: − 3.621 to − 0.808, P = 0.0023) and patients with LSM ≥8.2 kPa (β = − 4.074, 95% CI: − 6.237 to − 1.911, P = 0.0003). Moreover, the association was much stronger when the serum albumin was higher than 3.4 g/dL among patients with LSM ≥8.2 kPa (β = − 4.835, 95% CI: − 7.137 to − 2.533, P < 0.0001). Conclusion Our study revealed an inverse association between serum albumin and depression in CLD patients and this association differed according to liver histological changes. Serum albumin could be a warning marker for depressive symptoms in CLD patients. It is essential for taking corresponding intervention strategies.

show abstract

Analysis of liver steatosis analysis and controlled attenuation parameter for grading liver steatosis in patients with chronic hepatitis B

Cited by 7 publications

References 22 publications

Relationship Between Thyroid Hormone and Liver Steatosis Analysis Parameter in Obese Participants: A Case-Control Study

Relationship Between Thyroid Hormone and Liver Steatosis Analysis Parameter in Obese Participants: A Case-Control Study

A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease

The association between serum albumin and depression in chronic liver disease may differ by liver histology

Contact Info

Product

Resources

About